TuHURA Biosciences, Inc. (HURA) analyst actions
Rating and price-target actions on HURA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the HURA overview →
2 measured HURA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma | Press release | -0.00% | -6.75% | |
| TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) | Press release | -1.63% | -2.50% |
Keep exploring
More HURA: earnings → · SEC filings → · HURA overview →